Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2015
Event: Regulation FD Disclosure regarding a corporate presentation delivered at the Rodman & Renshaw 17th Annual Global Investment Conference.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the existence of a corporate presentation.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The report references a presentation attached as Exhibit 99.1 summarizing the development of GR-MD-02 for Non-Alcoholic Steatohepatitis (NASH) with Advanced Fibrosis and Cirrhosis.
Guidance, Outlook, and Risks
Management Commentary: The company provided a summary of drug development progress for GR-MD-02 in the attached presentation.
Legal Disclaimer: The information furnished under Item 7.01 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It shall not be deemed incorporated by reference in any other filing unless expressly referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for specific details on the GR-MD-02 development timeline and clinical data.
- Verify the company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the regulatory status of GR-MD-02 for NASH with Advanced Fibrosis and Cirrhosis.